Cenobamate for focal seizures - a game changer?

Affiliations

Comment

Jacqueline A French. Nat Rev Neurol. 2020 Mar.

. 2020 Mar;16(3):133-134.

doi: 10.1038/s41582-019-0309-7.

¹ NYU Langone School of Medicine, New York, NY, USA. jacqueline.french@nyulangone.org.

No abstract available

Comment on

Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.
Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, Steinhoff BJ, Kamin M. Krauss GL, et al. Lancet Neurol. 2020 Jan;19(1):38-48. doi: 10.1016/S1474-4422(19)30399-0. Epub 2019 Nov 14. Lancet Neurol. 2020. PMID: 31734103 Clinical Trial.

1. Krauss, G. L. et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 19, 38–48 (2019). - DOI
1. Kanner, A. M. et al. Practice guideline update summary: efficacy and tolerability of the new antiepileptic drugs II: treatment-resistant epilepsy: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 91, 82–90 (2018). - DOI
1. Löscher, W. & Schmidt, D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 52, 657–678 (2011). - DOI
1. Gazzola, D. M., Balcer, L. J. & French, J. A. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia 48, 1303–1307 (2007). - DOI
1. Sperling, M., Klein, P. & Kamin, M. Safety of cenobamate (YKP3089) as adjunctive treatment for uncontrolled partial seizures in a large, multicenter, open-label study. AES 2018 Annual Meeting Abstract Database [abstract 1.303] https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/500991 (2018).